CysEP inhibitors(Cysteine Endopeptidases inhibitors), DHODH inhibitors(Dihydroorotate dehydrogenase inhibitors), Electron transport complex I inhibitors

Therapeutic Areas

Infectious Diseases

Active Indication-

Inactive Indication

Malaria

Originator Organization

The University of Liverpool

Active Organization-

Inactive Organization

The University of Liverpool

GSK Plc

License Organization-

Drug Highest PhaseDiscontinuedPhase 1

First Approval Date-

Regulation-

Structure/Sequence

Molecular FormulaC20H22ClN3O

InChIKeyZVMMVSSEAMUNGI-UHFFFAOYSA-N

CAS Registry459133-38-1

Clinical Trials associated with N-tert butylisoquine

NCT00675064

/ CompletedPhase 1

Single-blind, Placebo-controlled, Randomized Study Testing Single Ascending Doses of GSK369796 in Healthy Subjects

This study will examine safety of single doses of GSK369796 in healthy subjects, along with some test to examine how quickly GSK369796 gets in your blood, and how long it takes your body to get rid of it.

Start Date02 May 2008

Sponsor / Collaborator

GSK Plc

[+1]

100 Clinical Results associated with N-tert butylisoquine

100 Translational Medicine associated with N-tert butylisoquine

100 Patents (Medical) associated with N-tert butylisoquine

3,333

Literatures (Medical) associated with N-tert butylisoquine

31 Dec 2025·Annals of Medicine

Neonatal lupus erythematosus: an acquired autoimmune disease to be taken seriously

Review

Author: Sun, Wenqiang ; Zhu, Xueping ; Fu, Changchang ; Jin, Xinyun ; Lei, Changda

AIMThis review aims to summarize the epidemiology, pathogenesis, clinical features, management, prognosis and regression of Neonatal lupus erythematosus (NLE) with a view to providing directions for standardized diagnosis, treatment and further research.METHODSWe conducted a comprehensive literature review of NLE. NLE-related peer-reviewed papers were searched through PubMed/Medline were searched up to November 2024.RESULTSNLE is a rare acquired autoimmune disease (AD) linked to organ damage from maternal autoantibodies crossing the placenta to the foetus. However, not all mothers have ADs or associated antibodies. The disease involves autoantibody-induced inflammation, apoptosis, fibrosis, calcium channel dysregulation in cardiomyocytes, and increased interferon expression. NLE incidence shows no sex difference, but there is a differential distribution of clinical features across ethnic groups. The frequency of organ involvement in NLE patients is more common in the cutaneous and cardiac. NLE also affects the haematological and hepatobiliary systems, and some patients may experience neurological and endocrinological involvement. Steroids and immunoglobulins can aid in the recovery of some patients. Proper use of antimalarials during prenatal and gestational periods may prevent or improve the prognosis of patients with congenital heart block (CHB). Implantation of a pacemaker is effective in maintaining cardiac function in children with complete atrioventricular block. Symptoms associated with NLE may improve with antibody depletion, but some patients may experience sequelae such as irreversible CHB, neuropsychiatric disorders and developmental delays. Universal screening for autoantibodies to Sjögren syndrome A or B autoantigens should be offered to women of childbearing age experiencing desiccation syndrome. Antibody-positive individuals require appropriate reproductive counselling and advice, along with close foetal monitoring starting at 16 weeks of gestation and postnatal prognostic follow-up.CONCLUSIONEpidemiologic investigations and clinical studies on NLE are currently inadequate, and large-scale epidemiologic investigations, prospective clinical studies, and basic research are needed in the future to improve the understanding of the disease and the standardization of its clinical management.

01 Jun 2025·Experimental Eye Research

Ripasudil does not induce phospholipid accumulation in human corneal epithelial cells

Article

Author: Kasano, Atsushi ; Watanabe, Yuichiro ; Kanazawa, Mizuho ; Tazoe, Fumiko ; Inoue, Toshihiro ; Inoue, Noriyuki

Rho-associated coiled-coil-containing protein kinase (Rho kinase; ROCK) inhibitors represent a novel class of glaucoma medications that lower intraocular pressure by enhancing aqueous humor outflow through the conventional outflow pathway. Netarsudil, a ROCK inhibitor, is known to induce cornea verticillata as an adverse effect in clinical settings. Unlike systemic amiodarone and antimalarials, topical agents do not typically induce the development of this corneal condition. This study investigated whether ripasudil, another ROCK inhibitor, induces cornea verticillata using a Chinese hamster-derived ovary cell line (CHO-K1), SV40 transformed human corneal epithelial cell line (HCE-T), and normal human primary corneal epithelial cells (HCEC-2). CHO-K1, HCE-T, and HCEC-2 were treated with ripasudil, netarsudil, or Y-27632 with varying concentrations (0.1, 0.3, 1, 3, 10, or 30 μM). Ripasudil and Y-27632 did not alter intracellular phospholipid levels at any concentration tested. Conversely, intracellular phospholipid accumulation was observed in cells treated with netarsudil. Netarsudil possesses chemical characteristics similar to those of cationic amphiphilic drugs, which are known to cause phospholipidosis. In contrast, ripasudil and Y-27632 lack these structural features. Our results suggest that ripasudil has a low likelihood of inducing cornea verticillata.

01 May 2025·Journal of Health Economics

Procurement institutions and essential drug supply in low and middle-income countries

Article

Author: Wang, Lucy Xiaolu ; Zahur, Nahim Bin

International procurement institutions play an important role in drug supply. We study price, delivery, and procurement lead time of drug products for major infectious diseases (antiretrovirals, antimalarials, antituberculosis, and antibiotics) in 106 developing countries from 2007-2017 across procurement institution types. We find that pooled procurement lowers prices: pooling internationally is most effective for small buyers and concentrated markets, while pooling within-country is most effective for large buyers and unconcentrated markets. Pooling can reduce delays, but at the cost of longer anticipated procurement lead times. Finally, pooled procurement is more effective for older drugs, compared to patent pooling institutions that target newer drugs. Our findings are robust to alternative fixed effects specifications, instrumental variable estimation, selection-on-unobservables tests, and additional analyses accounting for heterogeneity in demand elasticities across buyers and interactions with major global health initiatives.

News (Medical) associated with N-tert butylisoquine

28 Apr 2025

·www.prnewswire.com

Kangpu Biopharmaceuticals Received CDE Approval for Phase IIb Clinical Trial of KPG-818 in Moderate to Severe Cutaneous Manifestations of SLE

HEFEI, China, April 28, 2025 /PRNewswire/ -- Kangpu Biopharmaceuticals, Ltd. announced today that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has approved Phase IIb clinical trial of KPG-818 capsule for the treatment of moderate to severe cutaneous manifestations of systemic lupus erythematosus (SLE). About Cutaneous Manifestations of SLE SLE is a complex, heterogeneous, inflammatory, chronic autoimmune disease in which the body's immune system attacks its own tissues, including skin, joints, and kidneys. Skin is the second most frequently affected organ system of SLE. The majority of SLE patients experience cutaneous manifestations over the course of the disease. Cutaneous manifestations of SLE carries a significant burden with regard to psychosocial well-being and medical costs. Treatment options for cutaneous manifestations of SLE are limited, and current therapies (e.g., glucocorticoids, antimalarials, immunosuppressants) often lack efficacy or carry systemic side effects. There are tremendous unmet medical needs for novel therapeutics, especially an oral agent. About KPG-818 KPG-818 is a novel oral molecular glue modulator of the E3 ubiquitin ligase complex CRL4-CRBN. It demonstrated high binding affinity to CRBN and potent degradation of zinc-finger transcription factors Aiolos (IKZF3) and Ikaros (IKZF1). KPG-818 effectively regulates immune cells (B cells, T cells, and pDC cells) and the release of multiple cytokines, possessing immunomodulatory, anti-angiogenic and anti-tumor effects. In the Phase IIa clinical study in SLE patients completed in the US, KPG-818 was well tolerated and demonstrated promising preliminary efficacy in SLE patients with cutaneous manifestations. KPG-818 was well tolerated in healthy subjects in a Phase I clinical study completed in China. About Kangpu Biopharmaceuticals, Ltd. Kangpu Biopharmaceuticals, Ltd. is a clinical-stage company focused on the discovery and development of innovative therapeutics for the treatment of solid tumors, hematologic malignancies, autoimmune diseases, and inflammatory disorders through novel solutions, including targeted protein degradation. Kangpu has developed a robust pipeline of potential first-in-class and best-in-class drug candidates based on proprietary technology platforms, including NeoMIDES®, gDACs®, and X-SYNERGY®. For more information, please visit . SOURCE Kangpu Biopharmaceuticals WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Clinical ResultPhase 1Phase 2

19 Feb 2025

·www.drugs.com

Drug Can Stave Off Organ Damage From Lupus

WEDNESDAY, Feb. 19, 2025 -- Lupus can do irreversible harm to a person’s organs, damaging the lungs, kidneys, heart, liver and other vital organs through inflammation. But a newer lupus drug appears to protect patients from much of this organ damage, a new study suggests. Anifrolumab (brand name Saphnelo) reduced the risk of long-term organ damage progression by about 60% in patients with moderately to severely active lupus, researchers reported in a new study published this month in the Annals of the Rheumatic Disease s . “Anifrolumab plus standard of care (SOC) is effective at reducing organ damage accumulation and prolonging time to organ damage progression compared to SOC alone over 4 years,” a team led by Dr. Zahi Touma , an associate professor of medicine at the University of Toronto, concluded. People with lupus are typically treated using a combination of inflammation-quelling meds like steroids, antimalarials, immunosuppressants and nonsteroidal anti-inflammatory drugs, researchers said in background notes But these drugs don't stop organ damage from lupus, and in some cases might even contribute to it, researchers said. They decided to see if a newer drug, anifrolumab, might better help prevent organ damage if added to the existing brew used to treat lupus patients. The U.S. Food and Drug Administration (FDA) approved anifrolumab in 2021 for treatment of systemic lupus erythematosus, the most common form of lupus. Anifolumab Is a monoclonal antibody that works by blocking the receptors for type 1 interferon, a biochemical that plays a key role in promoting inflammation, researchers said. It’s given once a month via an IV drip, according to Drugs.com. For the trial, researchers compared 354 patients prescribed anifrolumab against 561 patients who received the usual care for lupus. All of these patients participated in the clinical trials that led to anifrolumab’s approval in the U.S. Results showed that people taking anifrolumab scored about 0.43 points lower on an index tracking organ damage caused by lupus. A 1-point increase in that index has previously been associated with a 34% increase in a lupus patient’s risk of premature death, researchers noted. Anifrolumab patients also had a 61% lower risk of having their organ damage get worse, results show. The study was paid for by AstraZeneca, which manufactures Saphnelo. Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

Clinical ResultDrug Approval

19 Feb 2025

·www.drugs.com

Saphnelo Can Stave Off Organ Damage From Lupus

WEDNESDAY, Feb. 19, 2025 -- Lupus can do irreversible harm to a person’s organs, damaging the lungs, kidneys, heart, liver and other vital organs through inflammation. But a newer lupus drug appears to protect patients from much of this organ damage, a new study suggests. Anifrolumab (brand name Saphnelo) reduced the risk of long-term organ damage progression by about 60% in patients with moderately to severely active lupus, researchers reported in a new study published this month in the Annals of the Rheumatic Disease s. “Anifrolumab plus standard of care (SOC) is effective at reducing organ damage accumulation and prolonging time to organ damage progression compared to SOC alone over 4 years,” a team led by Dr. Zahi Touma , an associate professor of medicine at the University of Toronto, concluded. People with lupus are typically treated using a combination of inflammation-quelling meds like steroids, antimalarials, immunosuppressants and nonsteroidal anti-inflammatory drugs, researchers said in background notes But these drugs don't stop organ damage from lupus, and in some cases might even contribute to it, researchers said. They decided to see if a newer drug, anifrolumab, might better help prevent organ damage if added to the existing brew used to treat lupus patients. The U.S. Food and Drug Administration (FDA) approved anifrolumab in 2021 for treatment of systemic lupus erythematosus, the most common form of lupus. Anifolumab Is a monoclonal antibody that works by blocking the receptors for type 1 interferon, a biochemical that plays a key role in promoting inflammation, researchers said. It’s given once a month via an IV drip, according to Drugs.com. For the trial, researchers compared 354 patients prescribed anifrolumab against 561 patients who received the usual care for lupus. All of these patients participated in the clinical trials that led to anifrolumab’s approval in the U.S. Results showed that people taking anifrolumab scored about 0.43 points lower on an index tracking organ damage caused by lupus. A 1-point increase in that index has previously been associated with a 34% increase in a lupus patient’s risk of premature death, researchers noted. Anifrolumab patients also had a 61% lower risk of having their organ damage get worse, results show. The study was paid for by AstraZeneca, which manufactures Saphnelo. Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

Clinical ResultDrug Approval

100 Deals associated with N-tert butylisoquine

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Malaria	Phase 1	-	The University of Liverpool	-
Malaria	Phase 1	-	The University of Liverpool	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


EULAR2024	Not Applicable	Rheumatoid Arthritis	1,671	Antimalarials	fkozudhaxa(twhtjsldru) = arlftnmaiw wkrtsolomx (zzdbtnslug ) View more	-	05 Jun 2024
RELESSER (EULAR2021)	Not Applicable	Systemic Lupus Erythematosus	-	Antimalarials	ecuipwjuqo(bezpkmccob) = dqnxtqdhkv azttbweqko (lxuiyhmfvv )	Positive	02 Jun 2021
ACR2016	Not Applicable	Primary Sjögren's syndrome	377	Antimalarials	ourmlozkkh(vovpsgdeft) = ocajhfshqv nxuqjfxfwx (iaoekhgvmh )	Positive	15 Nov 2016
ACR2016	Not Applicable	Primary Sjögren's syndrome	377	No Antimalarials	ourmlozkkh(vovpsgdeft) = zkknspipnq nxuqjfxfwx (iaoekhgvmh )	Positive	15 Nov 2016
EULAR2014	Not Applicable	Systemic Lupus Erythematosus	-	Antimalarials (Newly diagnosed SLE patients in Denmark)	(cysjscwprx) = jjxeynrtng eaijdkosza (dgygbwjryv )	-	11 Jun 2014
GLADEL (EULAR2011)	Not Applicable	Systemic Lupus Erythematosus	945	ANTIMALARIALS (Mestizo)	cqkbqddbws(vjktfeejva): HR = 1.65 (95% CI, 1.25 - 2.16)	-	25 May 2011
GLADEL (EULAR2011)	Not Applicable	Systemic Lupus Erythematosus	945	ANTIMALARIALS (Caucasian)	cqkbqddbws(vjktfeejva): HR = 1.65 (95% CI, 1.25 - 2.16)	-	25 May 2011
Pubmed	Not Applicable	Palindromic Rheumatism	113	Antimalarials	ecziawnrdj(pjasebhbbi) = wlazpgzlvi kpiudeixlm (hobzppdupz )	Positive	01 Jan 2000

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

N-tert butylisoquine

Overview

Basic Info

Structure/Sequence

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation